drugset / Trial / NCT07214779
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Timeline
- Start
- 2025-12-09
- Primary completion
- 2028-11-15
- Completion
- 2029-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | INCB123667 | Unknown | — | Oral |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pegylated liposomal doxorubicin (PLD) | Unknown | — | — |
| Subject | Topotecan | Small molecule | — | — |